Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication

To evaluate the outcomes of furazolidone- and amoxicillin-based quadruple therapy for treatment of ( ) infection and identify predictors of failed eradication. Patients with infection treated with furazolidone, amoxicillin, bismuth, and proton pump inhibitor therapy (January 2015 to December 2015) who received the C-urea breath test > 4 wk after treatment were evaluated. Demographic and clinical data including prior treatment attempts, medication adherence, alcohol and cigarette consumption during therapy, and treatment-related adverse events were recorded by reviewing medical records and telephone surveys. eradication rates for overall and subgroups were evaluated. Multivariate analysis was performed to identify independent predictors of failed eradication. Of the 992 patients treated and retested for infection, the overall eradication rate was 94.5% [95% confidence interval (CI): 94.1%-95.9%]. eradication rate of primary therapy was 95.0% (95%CI: 93.5%-96.5%), while that of rescue therapy was 91.3% (95%CI: 86.8%-95.8%). Among the 859 patients who completed the study protocol, 144 (17%) reported treatment-related adverse events including 24 (3%) leading to premature discontinuation. On multivariate analysis, poor medication adherence [adjusted odds ratio (AOR) = 6.7, 95%CI: 2.8-15.8], two or more previous treatments (AOR = 7.4, 95%CI: 2.2-24.9), alcohol consumption during therapy (AOR = 4.4, 95%CI: 1.5-12.3), and possibly smoking during therapy (AOR = 1.9, 95%CI: 0.9-4.3) were associated with failed eradication. Furazolidone- and amoxicillin-based quadruple therapy for infection in an area with a high prevalence of clarithromycin resistance demonstrated high eradication rates as primary and rescue therapies with a favorable safety profile. Patient education targeting abstinence from alcohol during therapy and strict medication adherence may further optimize eradication.